ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 30, 2005--InSite Vision Incorporated (AMEX:ISV) today announced positive top-line results from a pivotal phase 3 clinical trial of AzaSite(TM), a sterile, topical ophthalmic anti-infective solution containing 1.0% azithromycin formulated in DuraSite(R) (the Company's patented drug delivery system). In an international, controlled clinical trial, subjects with bacterial conjunctivitis (pink-eye) were treated with either AzaSite dosed twice a day for the first 2 days, followed by once a day for the next 3 days or 0.3% tobramycin dosed four times a day for 5 days. AzaSite demonstrated a clinical resolution rate of 80% as compared to 78% for tobramycin. This result shows that the clinical resolution rate of AzaSite is equivalent to tobramycin, the primary efficacy endpoint of the study, according to statistical criteria which were previously agreed to by the FDA. The bacterial eradication rate was also equivalent for both groups.